Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Status: open

14-021 - Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial - RTOG 0924

Treatment for Prostate Cancer

Contact Us Or call (251) 445-9834

Description

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

Demonstrate that prophylactic, neoadjuvant, androgen-deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) of patients with "unfavorable" intermediate-risk or "favorable" high-risk prostate cancer compared to NADT and high-dose prostate (P) and seminal vesicle (SV) radiation therapy (RT) using intensity-modulated RT (IMRT) or external-beam RT (EBRT) with a high-dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.

    Sponsors

    This trial is sponsored by Radiation Therapy Oncology Group.

    Providers Associated With This Trial

    Principle Investigator

      Sub Investigators

      This link will open in a new tab or window.